<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Infection and Immunity</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Infection and Immunity</journal-title><trans-title-group xml:lang="ru"><trans-title>Инфекция и иммунитет</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2220-7619</issn><issn publication-format="electronic">2313-7398</issn><publisher><publisher-name xml:lang="en">SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1453</article-id><article-id pub-id-type="doi">10.15789/2220-7619-BIW-1453</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>LEADING ARTICLE</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ПЕРЕДОВЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Born in Wuhan: lessons from COVID-19 epidemic in China</article-title><trans-title-group xml:lang="ru"><trans-title>Рожденная в Ухане: уроки эпидемии COVID-19 в Китае</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3223-8219</contrib-id><name-alternatives><name xml:lang="en"><surname>Semenov</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Семенов</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Alexander V. Semenov – PhD (Biology), Deputy Director for Innovation, Head of the Laboratory of Virology and Immunology HIV, St. Petersburg Pasteur Institute; Professor, Department of Immunology, Pavlov First St. Petersburg State Medical University</p><p>197101, St. Petersburg, Mira str., 14Phone: +7 (812) 233-20-92 </p></bio><bio xml:lang="ru"><p>Семенов Александр Владимирович – д.б.н., зам. директора по инновационной работе, зав. лабораторией иммунологии и вирусологии ВИЧ-инфекции ФБУН НИИ эпидемиологии и микробиологии имени Пастера; профессор кафедры иммунологии ГБОУ ВПО Первый Санкт-Петербургский Государственный медицинский университет им. акад. И.П. Павлова МЗ РФ</p><p>197101, Санкт-Петербург, ул. Мира, 14Тел.: 8 (812) 233-20-92 </p></bio><email>alexvsemenov@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2570-711X</contrib-id><name-alternatives><name xml:lang="en"><surname>Pshenichnaya</surname><given-names>N. Yu.</given-names></name><name xml:lang="ru"><surname>Пшеничная</surname><given-names>Н. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, MD (Medicine), Professor, Head of the Department of International Collaboration, National Research Medical Center of Phthisiopulmonology and Infectious Diseases, Moscow; Leading Researcher, Central Research Laboratory, Rostov State Medical University, Rostov-onDon</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, зав. отделом международного сотрудничества ФГБУ Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний Минздрава России, Москва; ведущий научный сотрудник центральной научноисследовательской лаборатории ФГБОУ ВО Ростовский государственный медицинский университет Минздрава России, г. Ростов-на-Дону</p></bio><email>natalia-pshenichnaya@yandex.ru</email><xref ref-type="aff" rid="aff3"/><xref ref-type="aff" rid="aff4"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">St. Petersburg Pasteur Institute</institution></aff><aff><institution xml:lang="ru">ФБУН НИИ эпидемиологии и микробиологии имени Пастера</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Pavlov First St. Petersburg State Medical University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">National Medical Research Center of Phthisiopulmonology and Infectious Diseases</institution></aff><aff><institution xml:lang="ru">ФГБУ Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Rostov State Medical University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО Ростовский государственный медицинский университет Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2020-05-22" publication-format="electronic"><day>22</day><month>05</month><year>2020</year></pub-date><volume>10</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>210</fpage><lpage>220</lpage><history><date date-type="received" iso-8601-date="2020-04-11"><day>11</day><month>04</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-04-12"><day>12</day><month>04</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2020, Semenov A.V., Pshenichnaya N.Y.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2020, Семенов А.В., Пшеничная Н.Ю.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="en">Semenov A.V., Pshenichnaya N.Y.</copyright-holder><copyright-holder xml:lang="ru">Семенов А.В., Пшеничная Н.Ю.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://iimmun.ru/iimm/article/view/1453">https://iimmun.ru/iimm/article/view/1453</self-uri><abstract xml:lang="en"><p>The COVID-19 epidemic curve in China can be divided into several stages. Despite transparency in informing the world public about clusters of undiagnosed viral pneumonia, the country’s health care at the first stage of the epidemic was not ready to provide adequate and rapid response for a fast increase in the number of patients with COVID-19, infection control measures were not fully implemented, which also led to a large number of nosocomial cases of infection among medical workers and patients. Socially vulnerable groups of the population did not refer for medical assistance in a timely manner due to the lack of the disease danger understanding and also in connection with the high cost for them of medical aid. At the second stage, simultaneously with the restrictive measures introduced by the government, the entire health care system was rebooted: free medical care for patients with COVID-19 was provided and the strictest infection control measures were implemented, multi-level contact tracking system using IT technologies was organized, and the capacity of hospitals was increased many times. Through the joint efforts of ministries, mass media, social networks and volunteer movements, an unprecedented social mobilization of the population was achieved. Strict implementation of the entire set of measures aimed at fighting the epidemic allowed to take it under strict control at the third stage and practically eliminate the epidemic after 2,5 months. China’s response to the COVID-19 epidemic can be useful to other countries, in fighting the current pandemic and in preparing for a response to biological threats in the future.</p></abstract><trans-abstract xml:lang="ru"><p>В статье приводится оценка эпидемии COVID-19 в Китае, которую можно разделить на несколько этапов. Несмотря на прозрачность в информировании мировой общественности, здравоохранение страны на первом этапе развития эпидемии оказалось не готово к быстрому росту числа больных с вирусной пневмонией, меры инфекционного контроля осществлялись не в полной мере, что также привело к большому числу случаев инфицирования среди медицинских работников. Социально уязвимые группы населения не обращались своевременно, в том числе, и по материальным причинам, за медицинской помощью. На втором этапе одновременно с ограничительными мерами, введенными государством произошла перезагрузка всей системы здравоохранения: стало осуществляться бесплатное оказание медицинской помощи пациентам с COVID-19 и обеспечение строжайших мер инфекционного контроля, многоуровневое отслеживание контактов с помощью IT-технологий, организовано многократное наращивание мощности госпиталей. Совместными усилиями министерств, средств массовой информации, социальных сетей и волонтерских движений была обеспечена беспрецендентная социальная мобилизация населения. Безукоснительное выполнение всего комплекса мер, направленных на борьбу с эпидемией, позволило взять на третьем этапе ее под жесткий контроль и практически ликвидировать, спустя 2,5 месяца. Ответные меры Китая на эпидемию COVID-19 могут быть полезны другим странам, в борьбе с текущей пандемией и в подготовке к ответу на биологические угрозы в будущем.</p></trans-abstract><kwd-group xml:lang="en"><kwd>COVID-19</kwd><kwd>epidemic curve</kwd><kwd>SARS-CoV-2</kwd><kwd>China</kwd><kwd>epidemic control and response</kwd><kwd>coronavirus</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>COVID-19</kwd><kwd>эпидемическая кривая</kwd><kwd>Китай</kwd><kwd>коронавирус</kwd><kwd>SARS-CoV-2</kwd><kwd>контроль над эпидемией</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>1. Ambrus A., Field E., Gonzalez R. Loss in the time of cholera: long-run impact of a disease epidemic on the urban landscape. Am. Econom. Rev., 2020, vol. 110, no. 2, pp. 475–525. doi: 10.1257/aer.20190759</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>2. Chan J.F.W., Yuan S., Kok K.H., To K.K.W., Chu H., Yang J., Tsoi H.W. A familial of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet, 2020. doi: 10.1093/infdis/jiaa077</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>3. Cucinotta D., Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed., 2020, vol. 91, no. 1, pp. 157–160. doi: 10.23750/abm.v91i1.9397</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>4. Diagnosis and treatment protocol for novel coronavirus pneumonia (Trial Version 6, Revised). The General Office of National Health Commission 18 February 2020, 13 p.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>5. Elfiky A. Sofosbuvir can inhibit the newly emerged coronavirus (2019-nCoV) in Wuhan, China. China (1/20/2020).</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>6. Guo Y.R., Cao Q.D., Hong Z.S., Tan Y.Y., Chen S.D., Jin H.J., Tan K.S., Wang D.Y., Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak — an update on the status. Military Med. Res., vol. 7, no. 1: 11. doi: 10.1186/s40779-020-00240-0</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>7. Kon W., Agarwal P.P. Chest imaging appearance of COVID-19 infection. Radiol. Cardiothorac. Imaging, 2020, vol. 2, no. 1: e200028. doi: 10.1148/ryct.2020200028</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>8. Li H., Wang Y.M., Xu J.Y., Cao B. Potential antiviral therapeutics for 2019 Novel Coronavirus. Zhonghua Jie He He Hu Xi Za Zhi = Chinese Journal of Tuberculosis and Respiratory Diseases, vol. 43, no. 3, pp. 170–172. doi: 10.3760/cma.j.issn.1001-0939.2020.03.004</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>9. Li Q., Guan X., Wu P., Wang X., Zhou L., Tong Y., Xing X. Early transmission dynamics in Wuhan, China, of novel coronavirusinfected pneumonia. N. Engl. J. Med., 2020, no. 382, pp. 1199–1207. doi: 10.1056/NEJMoa2001316</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>10. Linders D. From e-government to we-government: defining a typology for citizen coproduction in the age of social media. Government Information Quarterly, 2012, vol. 29, no. 4, pp. 446–454. doi: 10.1016/j.giq.2012.06.003</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>11. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). BioScience Trends, 2020. doi: 10.5582/bst.2020.01020</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>12. Marmot M. The influence of income on health: views of an epidemiologist. Health Affairs, 2002, vol. 21, no. 2, pp. 31–46.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>13. National Healthcare Security Administration. URL: http://www.gov.cn/xinwen/2020-01/30/content_5473177.htm (02.04.2020).</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>14. ProMED-mail. Pneumonia — China (Guangdong): RFI; ProMED-mail 2003; 10 Feb:2003 20030210.0357.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>15. ProMED-mail. Undiagnosed pneumonia — China (HU): RFI. ProMED-mail 2019; 30 Dec:2019 1230.6864153.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>16. Rong K., Zhou D., Tang K. We-governance and the block of COVID-2019 27.03.2020. URL: https://ssrn.com/abstract=3560879 (02.04.2020).</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>17. The novel coronavirus pneumonia emergency response epidemiology team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases COVID-19. China CCDC Weekly, 2020, no. 2, pp. 1–10. URL: http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51 (02.04.2020).</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>18. Wang Z., Tang K. Combating COVID-19: health equity matters. Nature Med., 2020. doi: 10.1038/s41591-020-0823-6</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>19. World Health Organization. Pneumonia of unknown cause — China. URL: www.who.int/csr/don/05-january-2020-pneumonia-ofunkown-cause-china/en (02.04.2020).</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>20. World Health Organization. Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19). 16–24 February 2020. URL: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf (02.04.2020).</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>21. World Health Organization. WHO statement regarding cluster of pneumonia cases in Wuhan, China. 9 January 2020. URL: https://www.who.int/china/news/detail/09-01-2020-who-statement-regarding-cluster-of-pneumonia-cases-in-wuhan-china (02.04.2020).</mixed-citation></ref></ref-list></back></article>
